Policy & Regulation
TFF Pharmaceuticals Summerizes Research on the Re-formulation of Remdesivir to a Dry Powder form for COVID-19 Antiviral Treatment
30 July 2020 - - US-based biopharmaceutical company TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) has reported the initial results of research evaluating the development of remdesivir as a dry powder for inhalation by Thin Film Freezing.

Findings of a study conducted by a team of researchers at the University of Texas at Austin's Division of Molecular Pharmaceutics and Drug Delivery, led by Robert O. Williams III, the inventor of the TFF technology, was published yesterday as a preprint in bioRxiv.

The research team developed inhaled forms of remdesivir for protecting and treating the respiratory mode of infection, including an amorphous brittle matrix powder made by Thin Film Freezing.

TFF Pharmaceuticals' Thin Film Freezing platform was designed to improve the solubility and absorption of poorly water-soluble drugs and is particularly suited to generate dry powder particles with properties targeted for inhalation delivery, especially to the deep lung, an area of extreme interest in respiratory medicine.

The TFF process results in a "Brittle Matrix Particle," which possesses low bulk density, high surface area, and typically an amorphous morphology. Allowing the particles to supersaturate when contacting the target site, such as lung tissue.

Based upon laboratory experiments the aerodynamic properties of the particles are such that the portion of a drug deposited to the deep lung has the potential to reach as high as 75%.

TFF Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing and commercialising innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform.

Early testing confirms that the TFF platform can significantly improve the solubility and absorption of poorly water-soluble drugs, a class of drugs that comprises approximately one-third of the major pharmaceuticals worldwide, thereby improving their pharmacokinetics.

TFF Pharmaceuticals has two lead drug candidates: Voriconazole Inhalation Powder and Tac-Lac Inhalation Powder.

The company plans to add to this pipeline by collaborating with large pharmaceutical partners.

The TFF Platform is protected by 41 patents issued or pending in the US and internationally.


Related Headlines